Biological AI is crossing from computation into the practice of science. This issue captures that trend from two directions.

JURA Bio crosses into the physical practice. Their AI doesn't just design proteins - it encodes itself into DNA synthesis chemistry and manufactures 10 quadrillion designs in a single reaction. Then it screens 20.9 billion antibody interactions in three days and learns from the results. The model's outputs aren't files. They're molecules.

BioReason-Pro crosses into the intellectual practice. It doesn't label a protein's function, but reasons through the evidence step by step, the way a biologist would, well enough that human experts preferred its explanations over curated database entries 79% of the time.

A Nature Biotechnology review, however, asks how far this crossing has actually gone - and is honest that much of biological AI still falls short.

Let's dive in.